In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%. Feb-25 35 calls and Feb-25 34 calls are the most active ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

UBS lowered the firm’s price target on Moderna (MRNA) to $78 from $96 and keeps a Buy rating on the shares. UBS believes Moderna’s oncology ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...